Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

Gene Logic is a leading integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray Services. Over 2/3rd of the top 25 Pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred genomics partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets & biomarkers.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Oncormed, Inc., is a genomics services company that characterizes newly discovered genes to establish their medical relevance and provides molecular profiling of patients for pharmacogenomic and therapeutic purposes. The company's mission is to accelerate the translation of cancer related genetic discoveries into clinically useful products and services through strategic collaborations with pharmaceutical, genomic and biotechnology companies.

Laboratoire HRA Pharma SA manufactures and distributes pharmaceutical products. Its products include contraceptive pills such as the pill of two days later and EllaOne. The company was founded by Andre Ulmann in 1996 and is headquartered in Paris, France.

Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. Its research programs include biomarker discovery, molecular diagnostics assays and drug development. The firm offers tests that can detect genetic alterations that drive tumour growth in all types of cancer. The company was founded by Jose Maestre, Santiago Ramon y Cajal, Rafael Rosell and Javier Rivela in 2006 and is headquartered in Barcelona, Spain.

LabGenomics Co., Ltd. engages in the provision of vitro diagnostic products and services. Its products include sample and bioinformatics analysis, diagnostic checks, and other products. The company was founded on March 29, 2002 and is headquartered in Seongnam-si, South Korea.

Genomic Vision is a biotechnology company that combines pioneering Molecular Combing, a proprietary single DNA molecule detection technology, with biomarker discovery to develop and commercialize novel genetic tests and research tools for life sciences. Genomic Vision’s products focus on DNA analysis and genetic testing in the fields of cancer, rare inherited disorders and pharmacogenomics.

Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with Ewing's sarcoma.

NHC Communications, Inc. manufactures network switching and test equipment for local telecom service providers, corporations and multi-tenant buildings. It also offers the XPoint product line geared for smaller network applications. The company was founded in 1986 and is headquartered in Mount-Royal, Canada

Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada

Nadathur Estates Pvt Ltd (Nadathur) is a private equity/venture capital firm founded in 1999 by Raghavan S. Nadathur. The firm is headquartered in Bangalore, India with additional office in Singapore.

SurExam Bio-Tech Co., Ltd. provides personalized medical system solutions focused on tumor molecular diagnostic products and clinical medicine testing services. Its products include medical kits, as well as it provides medical testing services. The company was founded on November 28, 2006 and is headquartered in Guangzhou, China.

Affymetrix, Inc. was an American company that manufactured DNA microarrays; it was based in Santa Clara, California, United States. The company was acquired by Thermo Fisher Scientific in March 2016. The company was founded by Stephen Fodor in 1992. It began as a unit in Affymax N.V. in 1991 by Fodor's group, which had in the late 1980s developed methods for fabricating DNA microarrays, called "GeneChip" according to the Affymetrix trademark, using semiconductor manufacturing techniques. The company's first product, an HIV genotyping GeneChip, was introduced in 1994 and the company went public in 1996. As a result of its pioneering work and the ensuing popularity of microarray products, Affymetrix derived significant benefit from its patent portfolio in this area.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help their clients realize their research goals in the rapidly evolving world of genomics. The company has become a world-leader in NGS services, with 1,800 employees and multiple locations across the globe. Novogene’s depth of experience has resulted in the ownership of 49 NGS-related patents, as well as the publishing of over 1850 customer research papers, often in well-respected publications such as Nature and Science. Company founder, Dr. Ruiqiang Li, is widely recognized as one of the world’s leading experts in genomics and bioinformatics, owning 12 patents and authoring over 90 peer-reviewed publications that have been cited >15,000 times. Best known for developing the software SOAP (Short Oligonucleotide Analysis Package) for ultra-fast sequence mapping, variation detection, and de novo genome assembly, Dr. Li has focused Novogene’s services on performing sequencing AND providing informatics to fully empower and enable their customers to move forward rapidly and effectively in their scientific endeavors.

Shanghai AIRD Gene Technology Co., Ltd., established on 2016-08-19, The scope of business includes engaging in genetic technology,Technology development in the field of biotechnology,technical consulting,technology transfer,Technical Services,drug development,laboratory reagent,Biological reagents for non-clinical diagnosis,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)research and development,Sales,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]